文献速递血栓与止血

重度COVID-19患者细胞外囊泡组织因子活性极高

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19.
PubMed 文献 · Blood Adv · 2021-01-01

本研究量化了111例住院COVID-19患者细胞外囊泡组织因子(EV-TF)活性,并与中度COVID-19及非COVID-19脓毒性休克患者(n=218)比较。重度COVID-19患者EV-TF活性显著高于中度患者,且与白细胞、D-二聚体和炎症参数相关,高EV-TF与血栓风险增加相关。COVID-19患者凝血病特征与脓毒性休克不同,表现为EV-TF和EV-纤溶活性升高而PAI-1未相应增加。

要点

  • 重度COVID-19患者EV-TF活性显著升高,与炎症和血栓风险相关。
  • COVID-19凝血病特征与脓毒性休克不同,EV-TF和EV-纤溶活性高而PAI-1未增加。
  • 结果支持住院患者系统预防性抗凝,重症可考虑强化抗凝。

核心结论

  • 重度COVID-19患者存在极高水平的EV-TF播散,支持系统预防性抗凝及重症强化抗凝的国际推荐。

研究设计与样本

  • 队列研究,纳入111例住院COVID-19患者,与中度COVID-19及非COVID-19脓毒性休克患者(n=218)比较。

主要发现

  • 重度COVID-19患者EV-TF活性中位数231 fM(25th-75th percentile 39-761),中度患者25 fM(12-59),P < .0001。
  • EV-TF与白细胞、D-二聚体和炎症参数相关。
  • 高EV-TF值在多变量模型中与血栓风险增加相关。
  • COVID-19患者较脓毒性休克患者EV-TF和EV-纤溶活性显著更高,且PAI-1未相应增加。

临床怎么用

  • 住院COVID-19患者应进行系统预防性抗凝,重度患者可考虑强化抗凝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19) has become one of the biggest public health challenges of this century. Severe forms of the disease are associated with a thrombo-inflammatory state that can turn into thrombosis. Because tissue factor (TF) conveyed by extracellular vesicles (EVs) has been implicated in thrombosis, we quantified the EV-TF activity in a cohort of hospitalized patients with COVID-19 (n = 111) and evaluated its link with inflammation, disease severity, and thrombotic events. Patients with severe disease were compared with those who had moderate disease and with patients who had septic shock not related to COVID-19 (n = 218). The EV-TF activity was notably increased in patients with severe COVID-19 compared with that observed in patients with moderate COVID-19 (median, 231 [25th to 75th percentile, 39-761] vs median, 25 [25th to 75th percentile, 12-59] fM; P < .0001); EV-TF was correlated with leukocytes, D-dimer, and inflammation parameters. High EV-TF values were associated with an increased thrombotic risk in multivariable models. Compared with patients who had septic shock, those with COVID-19 were characterized by a distinct coagulopathy profile with significantly higher EV-TF and EV-fibrinolytic activities that were not counterbalanced by an increase in plasminogen activator inhibitor-1 (PAI-1). Thus, this article is the first to describe the dissemination of extreme levels of EV-TF in patients with severe COVID-19, which supports the international recommendations of systematic preventive anticoagulation in hospitalized patients and potential intensification of anticoagulation in patients with severe disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Guervilly C, Bonifay A, Burtey S, et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 2021. PMID: 33560376. doi:10.1182/bloodadvances.2020003308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。